Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30
Reach urologists

52-Week Treatment with Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycaemic Control in Men with Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone - Abstract Show Comments PDF Print E-mail
  
Thursday, 16 July 2009

Men with the metabolic syndrome (MetS) and type 2 diabetes (T2D) often have low testosterone levels. Elevating low testosterone levels may improve features of the MetS and glycemic control. In a single blind, 52-week randomized clinical trial, the effects of supervised diet and exercise (D&E) with or without transdermal testosterone administration on components of the MetS in hypogonadal men with the MetS and newly diagnosed T2D were assessed. 32 hypogonadal men (total testosterone <12.0 nmol/L) with the MetS as defined by the Adult Treatment Panel-III and the International Diabetes Federation, and newly diagnosed T2D received supervised D&E but 16 in combination with testosterone gel 50 mg once daily (n=16). No glucose lowering agents were administered prior to or during the study period. Outcome measures were components of the MetS as defined by the ATPIII and IDF. Serum testosterone, HbA1c, fasting plasma glucose, HDL-cholesterol, and triglyceride concentrations, and the waist circumference improved in both treatment groups after 52-weeks of treatment. Addition of testosterone significantly further improved these measures compared to D&E alone. All D&E+T patients reached the HbA1c goal of <7.0%, 87.5% reached an HbA1c <6.5%. Based on ATPIII, 81.3% of the patients randomized to D&E+T no longer matched the criteria of the MetS, whereas 31.3% of the D&E alone patients did. Additionally, testosterone treatment improved insulin sensitivity, adiponectin and high-sensitivity C-reactive protein. Addition of testosterone to supervised D&E results in greater therapeutic improvements of glycaemic control and reverses the MetS after 52-weeks of treatment in hypogonadal patients with the MetS and newly diagnosed T2D.

Written by:
Heufelder AE, Saad F, Bunck MC, Gooren LJ   Are you the author?

Reference:
J Androl. 2009 Jul 3. (Epub ahead of print)
10.2164/jandrol.108.007005

PubMed Abstract
PMID: 19578132

UroToday.com Androgen Deficiency Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 1
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
5 (1 votes)


Bookmark and Share

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts


Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities